Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$73.22 USD

73.22
407,321

-0.74 (-1.00%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $73.21 -0.01 (-0.01%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Urmimala Biswas headshot

Hill-Rom (HRC) Rides on International Growth, New Launches

by Urmimala Biswas

Hill-Rom (HRC) launches RetinaVue 700 Imager, EarlySense and WatchCare in 2019.

LHC Group Expands Partnership With Ochsner Health System

by Zacks Equity Research

LHC Group (LHCG) sees major expansion in partnerships of late.

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

by Zacks Equity Research

DexCom (DXCM) raises its 2019 revenue and EPS guidance.

Here's Why You Should Hold on to Allscripts Stock for Now

by Zacks Equity Research

Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.

Here's Why You Should Bet on Integer Holdings Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

LHC Group Expands Partnership With Tennessee-Based Medalogix

by Zacks Equity Research

Management at LHC Group (LHCG) expects to complete the expansion by the first quarter of 2020.

Here's Why You Should Invest in Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

McKesson, Walgreens Form JV for European Pharmaceutical Unit

by Zacks Equity Research

The VA selects McKesson (MCK) as their prime pharmaceutical supplier.

NextGen Healthcare Boosts Patient Care With CHC Strategies

by Zacks Equity Research

NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.

LHC Group Set to Gain From Expansion of LifePoint Health JV

by Zacks Equity Research

LHC Group (LHCG) expects approximately $5.4 million in annualized revenues from this transaction.

Are You Looking for a Top Momentum Pick? Why Conmed (CNMD) is a Great Choice

by Zacks Equity Research

Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why You Should Retain NextGen Healthcare for Now

by Zacks Equity Research

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Here's Why You Should Retain Wright Medical Stock For Now

by Zacks Equity Research

Wright Medical (WMGI) is gaining traction from strong international presence and robust product portfolio. However, adverse forex continues to raise concerns.

Here's Why You Should Hold on to Ecolab (ECL) Stock for Now

by Zacks Equity Research

Ecolab (ECL) slashes 2019 EPS view owing to foreign exchange headwinds.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Here's Why You Should Hold on to HealthEquity (HQY) for Now

by Zacks Equity Research

Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.

HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3

by Zacks Equity Research

Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.

Here's Why You Should Hold On to HMS Holdings (HMSY) Stock

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services. However, high debt continues to raise concerns.

Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now

by Zacks Equity Research

Buoyed by a solid fiscal third quarter, Veeva (VEEV) raises its fiscal 2020 revenue guidance.

Intuitive Surgical (ISRG) Boosts da Vinci System With FDA Nod

by Zacks Equity Research

Intuitive Surgical (ISRG) is likely to strengthen its da Vinci surgical system with the recent FDA nod.

Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva (VEEV) gains from solid segmental contributions in fiscal third quarter, raises fiscal 2020 view.

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.

Here's Why You Should Hold on to Varian (VAR) Stock for Now

by Zacks Equity Research

Varian (VAR) gains from Oncology unit, deals with weakness in the Proton Therapy segment.

Here's Why You Should Hold on to Pacific Biosciences Stock

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.